We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+7.96%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$78.8B
AUM Growth
-$135M
(-0.17%)
Cap. Flow
-$4.13B
Cap. Flow
% of AUM
-5.25%
Top 10 Holdings %
Top 10 Hldgs %
14.64%
Holding
3,669
New
809
Increased
1,002
Reduced
1,102
Closed
643
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$807M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$497M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$390M |
| 4 |
Kenvue
KVUE
|
+$379M |
| 5 |
Broadcom
AVGO
|
+$324M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$409M |
| 2 |
Visa
V
|
+$354M |
| 3 |
Advanced Micro Devices
AMD
|
+$328M |
| 4 |
Meta Platforms (Facebook)
META
|
+$317M |
| 5 |
Lockheed Martin
LMT
|
+$316M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 11.61% |
| 2 | Consumer Discretionary | 9.64% |
| 3 | Healthcare | 8.17% |
| 4 | Industrials | 8.1% |
| 5 | Financials | 8.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Ultragenyx Pharmaceutical
RARE
$2.63B
| $12M | 0.02% |
+520,054
| New | +$17.1M |
|
902
NextDecade
NEXT
$1.8B
| $11.9M | 0.02% |
2,267,259
+2,189,095
| +2,801% | +$13.1M |
|
903
CALL
Lam Research
LRCX
$388B
| $11.9M | 0.02% |
69,800
-211,100
| -75% | -$32.8M |
|
904
Nektar Therapeutics
NKTR
$2.53B
| $11.9M | 0.02% |
282,021
+99,207
| +54% | +$5.55M |
|
905
Alignment Healthcare
ALHC
$2.78B
| $11.9M | 0.02% |
600,462
-1,030,358
| -63% | -$18.5M |
|
906
Palo Alto Networks
PANW
$311B
| $11.8M | 0.02% |
64,154
+37,006
| +136% | +$7.47M |
|
907
Merit Medical Systems
MMSI
$5.46B
| $11.8M | 0.01% |
133,438
+56,828
| +74% | +$4.84M |
|
908
PUT
Alkermes
ALKS
$8.31B
| $11.7M | 0.01% |
+419,700
| New | +$12.6M |
|
909
PUT
Strategy Inc
MSTR
$37.9B
| $11.7M | 0.01% |
77,200
+26,300
| +52% | +$6.05M |
|
|
CNTA
910
DELISTED
Centessa Pharmaceuticals
CNTA
| $11.7M | 0.01% |
468,815
-336,796
| -42% | -$8.53M |
|
911
TPG
TPG
$8.18B
| $11.7M | 0.01% |
183,039
-1,095,126
| -86% | -$64.6M |
|
912
Genmab
GMAB
$19.2B
| $11.7M | 0.01% |
+379,364
| New | +$11.8M |
|
913
CALL
Wayfair
W
$14.3B
| $11.7M | 0.01% |
116,100
-131,300
| -53% | -$12.6M |
|
914
Estee Lauder
EL
$31.7B
| $11.6M | 0.01% |
+111,225
| New | +$10.8M |
|
915
SiriusXM
SIRI
$9.67B
| $11.6M | 0.01% |
580,841
+507,950
| +697% | +$10.9M |
|
916
CubeSmart
CUBE
$9.24B
| $11.6M | 0.01% |
+321,962
| New | +$12.2M |
|
917
PUT
Coca-Cola
KO
$373B
| $11.6M | 0.01% |
165,700
+156,900
| +1,783% | +$10.9M |
|
918
Atlas Energy Solutions
AESI
$1.54B
| $11.5M | 0.01% |
1,223,333
+1,123,767
| +1,129% | +$11.4M |
|
919
HNI Corp
HNI
$3.6B
| $11.5M | 0.01% |
273,961
+247,361
| +930% | +$10.4M |
|
920
ServiceNow
NOW
$131B
| $11.5M | 0.01% |
75,036
+34,566
| +85% | +$5.93M |
|
|
PVLA
921
Palvella Therapeutics
PVLA
$2.25B
| $11.4M | 0.01% |
108,880
-57,655
| -35% | -$4.92M |
|
922
Labcorp
LH
$26.1B
| $11.4M | 0.01% |
45,400
-72,854
| -62% | -$19.3M |
|
923
Datadog
DDOG
$89.6B
| $11.4M | 0.01% |
83,646
+12,487
| +18% | +$1.97M |
|
924
News Corp Class A
NWSA
$15.4B
| $11.4M | 0.01% |
435,380
+422,148
| +3,190% | +$11.1M |
|
925
Range Resources
RRC
$9.52B
| $11.4M | 0.01% |
322,406
-111,852
| -26% | -$4.17M |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Balyasny Asset Management held 3,669 positions worth $78.8B, down 0.17% from $78.9B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Balyasny Asset Management withdrew a net $4.13B in Q4 2025, closing 643 positions and reducing 1,102 holdings. Its most notable exit was Mr. Cooper, an estimated $277M position sold in full.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 12% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Balyasny Asset Management opened a new position in Avidity Biosciences worth $436M.
- Balyasny Asset Management's largest Q4 2025 buy was Avidity Biosciences: 6,040,590 shares worth $436M.
- Balyasny Asset Management added most to Amazon in Q4 2025, an estimated $807M increase.
- Balyasny Asset Management's biggest Q4 2025 reduction was Apple, cutting an estimated $409M.
- Balyasny Asset Management fully exited Mr. Cooper in Q4 2025, selling an estimated $277M.
- Balyasny Asset Management's ten largest holdings make up 15% of its $78.8B portfolio in Q4 2025.
- Balyasny Asset Management opened 809 new positions and closed 643 in Q4 2025.
- Balyasny Asset Management's portfolio value fell 0.17% quarter-over-quarter to $78.8B.
Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.